Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Operating Margin (2017 - 2025)

Puma Biotechnology's Operating Margin history spans 9 years, with the latest figure at 22.67% for Q4 2025.

  • For Q4 2025, Operating Margin rose 5.0% year-over-year to 22.67%; the TTM value through Dec 2025 reached 16.33%, up 290.0%, while the annual FY2025 figure was 16.33%, 290.0% up from the prior year.
  • Operating Margin reached 22.67% in Q4 2025 per PBYI's latest filing, up from 17.57% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 27.41% in Q3 2024 to a low of 31.16% in Q2 2021.
  • Average Operating Margin over 5 years is 7.9%, with a median of 10.2% recorded in 2023.
  • Peak YoY movement for Operating Margin: plummeted -4126bps in 2021, then surged 5142bps in 2022.
  • A 5-year view of Operating Margin shows it stood at 0.91% in 2021, then soared by 1358bps to 11.43% in 2022, then skyrocketed by 79bps to 20.5% in 2023, then rose by 10bps to 22.62% in 2024, then rose by 0bps to 22.67% in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Operating Margin are 22.67% (Q4 2025), 17.57% (Q3 2025), and 12.66% (Q2 2025).